Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- Citation:
- J Clin Oncol vol 34 (6) 542-549
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- 937 is parent abstract
- Pharmas:
- Grants:
- CA33601, P30 CA016672, 1U10CA180801, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA180801, P50 CA058223, P50-CA58223, U10CA180882, P30 CA008748, U10 CA180791, 1U10CA180838, U10 CA180818, 1U10CA180867, U10 CA180882, U10CA180821, 1U10CA180791, U10 CA180867, U10 CA180838, U10 CA180888, CA31946
- Corr. Author:
- Authors:
- Lisa A. Carey Donald A. Berry Constance T. Cirrincione William T. Barry Brandelyn N. Pitcher Lyndsay N. Harris David W. Ollila Ian E. Krop Norah Lynn Henry Douglas J. Weckstein Carey K. Anders Baljit Singh Katherine A. Hoadley Michael Iglesia Maggie Chon U. Cheang Charles M. Perou Eric P. Winer Clifford A. Hudis
- Networks:
- LAPS-CT018, LAPS-MO011, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-UT003, NH038
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Rc, Bc6, Bc8, ORIGINAL REPORTS, Rapid Communication